Pfizer Chief Executive Officer Albert Bourla said his company supports Joe Biden’s $1.9 trillion coronavirus-focused plan that is intended to boost vaccination efforts and address the pandemic.
Moncef Slaoui, the GlaxoSmithKline vaccines veteran who has helmed the federal government’s Operation Warp Speed Covid-19 vaccine program, is stepping down from the role ahead of the inauguration of President-elect Joe Biden.
Publicly traded companies that have been heavily involved in developing therapies and vaccines for Covid-19 have experienced significant spikes in their stock prices from March 2020 to January 2021, including Germany’s BioNTech, which surged 187% in one year.
The United States lost more than 22,000 lives to Covid-19 for the week ended Jan. 10, setting a record for the second week in a row, as new cases also hit a weekly high.
The United Kingdom, which was the first to grant authorization to the vaccine developed by Pfizer and Moderna, is expected to give the green light to the vaccine developed by AstraZeneca and Oxford University this week.
The chief executive of Germany’s BioNTech SE said the biggest challenge facing the company and partner Pfizer Inc. now that their Covid-19 vaccine is authorized for use in the United States will be to scale up manufacturing to meet huge demand.
U.S. Health Secretary Alex Azar said if pharmaceutical company Pfizer Inc. submits interim Covid-19 vaccine to health regulators as quickly as expected, the U.S. government anticipates the beginning of vaccinating Americans in December.
Pfizer Inc.’s experimental Covid-19 vaccine was more than 90% effective based on initial trial results, the company said, a major victory in the fight against a pandemic that has killed more than 1 million people and battered the world’s economy.